Authors: A. Pirshtuk 1; T. Büchler 1; V. Vymetálková 2 Authors‘ workplace: Onkologická klinika 2. LF UK a FN Motol a Homolka, Praha 1; Oddělení molekulární biologie nádorů, Ústav Experimentální medicíny AV ČR, Praha 2 Published in: Klin Onkol 2026; 39(2): 105-111 Category: Review doi: https://doi.org/10.48095/ccko2026105
Background: Colorectal cancer (CRC) remains one of the most common malignancies in the Czech Republic. Despite advances in surgical treatment, the risk of recurrence persists, mainly due to minimal residual disease (MRD). Current surveillance strategies, including colonoscopy, CT imaging, and serum tumor markers (CEA, CA19-9), demonstrate limited sensitivity and specificity. In recent years, circulating tumor DNA (ctDNA) has emerged as a promising biomarker with significant prognostic and predictive potential. Methodology: This review was prepared based on a systematic literature search in PubMed, Web of Science, ScienceDirect, Scopus, and clinicaltrials.gov covering the period 2005–2025. Observational studies, retrospective analyses, and randomized clinical trials evaluating the prognostic and predictive role of ctDNA in patients with CRC were included. Results: Available studies confirm that the presence of ctDNA after curative resection of CRC is a strong predictor of early recurrence and worse survival, whereas ctDNA negativity reliably identifies patients at low risk. Prospective projects (VICTORI, GALAXY, COSMOS) demonstrated that ctDNA can predict relapse several months earlier than standard methods. The BESPOKE CRC study highlighted that only patients with positive ctDNA significantly benefit from adjuvant chemotherapy. The randomized DYNAMIC trial proved that a ctDNA-guided approach enables safe de-escalation of adjuvant therapy without compromising outcomes. Ongoing studies (PEGASUS, SAGITTARIUS, TRACC, DYNAMIC-III, ALTAIR, VEGA) are testing the efficacy of escalation and de-escalation strategies. Conclusions: ctDNA is a highly promising biomarker for early MRN detection, risk stratification, and the individualization of adjuvant therapy in CRC patients. Its implementation in routine clinical practice, however, requires confirmation from ongoing randomized trials and validation in the Czech setting, where the use of ctDNA currently remains limited primarily to research.
colorectal cancer – Adjuvant chemotherapy – Circulating tumor DNA – liquid biopsy – minimal residual disease – personalized oncology
1. SVOD. Portál epidemiologie novotvarů v ČR. 2024 [online]. Dostupné z: https: //www.svod.cz.
2. Yakabe T, Nakafusa Y, Sumi K et al. Clinical significance of CEA and CA19-9 in postoperative follow-up of colorectal cancer. Ann Surg Oncol 2010; 17 (9): 2349–2356. doi: 10.1245/s10434-010-1004-5.
3. Brenner H, Kloor M, Pox CP. Colorectal cancer. Lancet 2014; 383 (9927): 1490–1502. doi: 10.1016/S0140-6736 (13) 61649-9.
4. Smith-Bindman R, Chu PW, Azman Firdaus H et al. Projected lifetime cancer risks from current computed tomography imaging. JAMA Intern Med 2025; 185 (6): 710–719. doi: 10.1001/jamainternmed.2025.0505.
5. Ho Seung K, Ro Lee M. Diagnostic accuracy of elevated serum carcinoembryonic antigen for recurrence in postoperative stage II colorectal cancer patients: comparison with stage III. Ann Coloproctol 2013; 29 (4): 155–159. doi: 10.3393/ac.2013.29.4.155.
6. Yokota M, Morikawa A, Matsuoka H et al. Is frequent measurement of tumor markers beneficial for postoperative surveillance of colorectal cancer? Int J Colorectal Dis 2023; 38 (1): 75. doi: 10.1007/s00384-023-04356-2.
7. Okamura R, Hasegawa S, Hida K et al. The role of periodic serum CA19-9 test in surveillance after colorectal cancer surgery. Int J Clin Oncol 2017; 22 (1): 96–101. doi: 10.1007/s10147-016-1027-4.
8. Park IJ, Choi GS, Lim KH et al. Serum carcinoembryonic antigen monitoring after curative resection for colorectal cancer: clinical significance of the preoperative level. Ann Surg Oncol 2009; 16 (11): 3087–3093. doi: 10.1245/s10434-009-0625-z.
9. Primrose JN, Perera R, Gray A et al. Effect of 3 to 5 years of scheduled CEA and CT follow-up to detect recurrence of colorectal cancer: the FACS randomized clinical trial. JAMA 2014; 311 (3): 263–270. doi: 10.1001/jama.2013. 285718.
10. Mauri G, Vitiello PP, Sogari A et al. Liquid biopsies to monitor and direct cancer treatment in colorectal cancer. Br J Cancer 2022; 127 (3): 394–407. doi: 10.1038/s41416-022-01769-8.
11. Diaz LA, Bardelli A. Liquid biopsies: genotyping circulating tumor DNA. J Clin Oncol 2014; 32 (6): 579–586. doi: 10.1200/JCO.2012.45.2011.
12. Vymetalkova V, Cervena K, Bartu L et al. Circulating cell--free DNA and colorectal cancer: a systematic review. Int J Mol Sci 2018; 19 (11): 3356. doi: 10.3390/ijms19113356.
13. Martínez-Castedo B, Camblor DG, Martín-Arana J et al. Minimal residual disease in colorectal cancer. Tumor-informed versus tumor-agnostic approaches: unraveling the optimal strategy. Ann Oncol 2025; 36 (3): 263–276. doi: 10.1016/j.annonc.2024.12.006.
14. Nakamura Y, Tsukada Y, Matsuhashi N et al. Colorectal cancer recurrence prediction using a tissue-free epigenomic minimal residual disease assay. Clin Cancer Res 2024; 30 (19): 4377–4387. doi: 10.1158/1078-0432.CCR-24-1651.
15. Ryan BM, Lefort F, McManus R et al. A prospective study of circulating mutant KRAS2 in the serum of patients with colorectal neoplasia: strong prognostic indicator in postoperative follow up. Gut 2003; 52 (1): 101–108. doi: 10.1136/gut.52.1.101.
16. Lecomte T, Berger A, Zinzindohoué F et al. Detection of free-circulating tumor-associated DNA in plasma of colorectal cancer patients and its association with prognosis. Int J Cancer 2002; 100 (5): 542–548. doi: 10.1002/ijc.10526.
17. Mauri G, Vitiello PP, Sogari A et al. Liquid biopsies to monitor and direct cancer treatment in colorectal cancer. Br J Cancer 2022; 127 (3): 394–407. doi: 10.1038/s41416-022-01769-8.
18. Diehl F, Schmidt K, Choti MA et al. Circulating mutant DNA to assess tumor dynamics. Nat Med 2008; 14 (9): 985–990. doi: 10.1038/nm.1789.
19. Taieb J, Souglakos J, Boukovinas I et al. Combined analyses of circulating tumor DNA and immunoscore in patients with stage III colon cancer: a post hoc analysis of the PRODIGE-GERCOR IDEA-France/HORG-IDEA-Greece trials. J Clin Oncol 2025; 43 (13): 1234–1245. doi: 10.1200/JCO.24.00648.
20. Taniguchi H, Nakamura Y, Kotani D et al. CIRCULATE-Japan: circulating tumor DNA-guided adaptive platform trials to refine adjuvant therapy for colorectal cancer. Cancer Sci 2021; 112 (7): 2915–2920. doi: 10.1111/cas.14926.
21. Solar Vasconcelos JP, Titmuss E, Navarro F et al. Circulating tumor DNA (ctDNA) kinetics in colorectal cancer treated with curative intent in the VICTORI study with an ultrasensitive MRD assay. J Clin Oncol 2024; 42 (Suppl 16): e15625. doi: 10.1200/JCO.2024.42.16_suppl.e15625.
22. Solar Vasconcelos JP, Titmuss E, Navarro F et al. Identifying the optimal post-surgical timing of molecular residual disease (MRD) detection in colorectal cancer using an ultra-sensitive assay: interim results from the VICTORI study. J Clin Oncol 2025; 43 (Suppl 4): 275. doi: 10.1200/JCO.2025.43.4_suppl.275.
23. Nakamura Y, Watanabe J, Akazawa N et al. ctDNA-based molecular residual disease and survival in resectable colorectal cancer. Nat Med 2024; 30 (11): 3272–3283. doi: 10.1038/s41591-024-03254-6.
24. Kataoka K, Mori K, Nakamura Y et al. Survival benefit of adjuvant chemotherapy based on molecular residual disease detection in resected colorectal liver metastases: subgroup analysis from CIRCULATE-Japan GALAXY. Ann Oncol 2024; 35 (11): 1015–1025. doi: 10.1016/j.annonc.2024.08.2240.
25. Nakamura Y, Tsukada Y, Matsuhashi N et al. Colorectal cancer recurrence prediction using a tissue-free epigenomic minimal residual disease assay. Clin Cancer Res 2024; 30 (19): 4377–4387. doi: 10.1158/1078-0432.CCR-24-1651.
26. Tsukada Y, Matsuhashi N, Murano T et al. Impact of postoperative integrated genomic and epigenomic signatures of circulating tumor DNA on recurrence in resected colorectal cancer: initial report of a prospective ctDNA monitoring study COSMOS-CRC-01. J Clin Oncol 2022; 40 (Suppl 4): 168. doi: 10.1200/JCO.2022.40.4_suppl.168.
27. Aushev VN, Ensor J, Sanchez SA et al. Circulating tumor DNA for detection of molecular residual disease in patients with stage II/III colorectal cancer: final analysis of the BESPOKE CRC sub-cohort. Gastroenterology 2025; 169 (1): S127. doi: 10.1016/S0016-5085 (25) 01235-1.
28. Verschoor N, Bos MK, Oomen-de Hoop E et al. A review of trials investigating ctDNA-guided adjuvant treatment of solid tumors: the importance of trial design. Eur J Cancer 2024; 207 : 114159. doi: 10.1016/j.ejca.2024.114159.
29. Tie J, Cohen JD, Lahouel K et al. Circulating tumor DNA analysis guiding adjuvant therapy in stage II colon cancer. N Engl J Med 2022; 386 (24): 2261–2272. doi: 10.1056/NEJMoa2200075.
30. Tie J, Wang Y, Loree JM et al. ctDNA-guided adjuvant chemotherapy escalation in stage III colon cancer: primary analysis of the ctDNA-positive cohort from the randomized AGITG DYNAMIC-III trial (intergroup study of AGITG and CCTG). J Clin Oncol 2025; 43 (Suppl 16): 3503. doi: 10.1200/JCO.2025.43.16_suppl.3503.
31. Clinical Trials. Circulating tumor DNA based adjuvant chemotherapy in stage II colon cancer patients: the MEDOCC-CrEATE trial (CrEATE). 2025 [online]. Dostupné z: https: //clinicaltrials.gov/study/NCT06434896.
32. Clinical Trials. IMPROVE intervention trial implementing non-invasive circulating tumor DNA analysis to optimize the operative and postoperative treatment for patients with colorectal cancer (IMPROVE-IT). 2025 [online]. Dostupné z: https: //clinicaltrials.gov/study/NCT03748680.
33. Clinical Trials. Circulating tumor DNA testing in predicting treatment for patients with stage IIA colon cancer after surgery. 2025 [online]. Dostupné z: https: //clinicaltrials.gov/study/NCT04068103.
34. Bando H, Watanabe J, Kotaka M et al. A randomized, double-blind, phase III study comparing trifluridine/tipiracil (FTD/TPI) versus placebo in patients with molecular residual disease following curative resection of colorectal cancer (CRC): the ALTAIR study. J Clin Oncol 2025; 43 (Suppl 4): LBA22. doi: 10.1200/JCO.2025.43.4_suppl.LBA22.
35. Slater S, Bryant A, Chen HC et al. ctDNA guided adjuvant chemotherapy versus standard of care adjuvant chemotherapy after curative surgery in patients with high risk stage II or stage III colorectal cancer: a multi-centre, prospective, randomised control trial (TRACC Part C). BMC Cancer 2023; 23 (1): 257. doi: 10.1186/s12885-023-10699-4.
36. Slater S, Bryant A, Aresu M et al. Tissue-free liquid biopsies combining genomic and methylation signals for minimal residual disease detection in patients with early colorectal cancer from the UK TRACC part B study. Clin Cancer Res 2024; 30 (16): 3459–3469. doi: 10.1158/1078-0432.CCR-24-0226.
37. Clinical Trials. Post-surgical liquid biopsy-guided treatment of stage III and high-risk stage II colon cancer patients: the PEGASUS trial. 2025 [online]. Available from: https: //clinicaltrials.gov/study/NCT04259944.
38. Lonardi S, Pietrantonio F, Tarazona L et al. The PEGASUS trial: post-surgical liquid biopsy-guided treatment of stage III and high-risk stage II colon cancer patients. J Clin Oncol 2020; 38 (Suppl 15): TPS4124. doi: 10.1200/JCO.2020.38.15_suppl.TPS4124.
39. Montagut CO, Tamberi S, Leone F et al. A precision medicine trial leveraging tissue and blood-based tumor genomics to optimize treatment in resected stage III and high-risk stage II colon cancer (CC) patients: the SAGITTARIUS trial. J Clin Oncol 2025; 43 (Suppl 16): TPS3647. doi: 10.1200/JCO.2025.43.16_suppl.TPS3647.
40. Tie J, Wang Y, Loree JM et al. ctDNA-guided adjuvant chemotherapy escalation in stage III colon cancer: primary analysis of the ctDNA-positive cohort from the randomized AGITG DYNAMIC-III trial (intergroup study of AGITG and CCTG). J Clin Oncol 2025; 43 (Suppl 16): 3503. doi: 10.1200/JCO.2025.43.16_suppl.3503.
41. Tie J, Cohen J, Wang Y et al. Circulating tumor DNA analysis informing adjuvant chemotherapy in locally advanced rectal cancer: the randomized AGITG DYNAMIC-rectal study. J Clin Oncol 2024; 42 (Suppl 3): 12. doi: 10.1200/JCO.2024.42.3_suppl.12.
Don‘t have an account? Create new account
Enter the email address that you registered with. We will send you instructions on how to set a new password.
